China Diabetes Care Drugs And Devices Market: Market Size & Forecast 2026

China has one of the world's highest numbers of people living with diabetes, with estimates suggesting over 140 million adults affected, creating substantial demand for diabetes care products. The market encompasses both pharmaceutical treatments and medical devices, including insulin and oral antidiabetic drugs alongside blood glucose monitoring systems, insulin pens, and insulin pumps. As one of the largest diabetes care markets globally, China's segment is characterized by a mix of multinational pharmaceutical companies and growing domestic manufacturers.

• •China has the world's largest diabetic population, with prevalence rates among adults estimated at over 12%
• •The market includes insulin therapies, oral antidiabetic drugs, blood glucose meters, continuous glucose monitors, and insulin delivery devices
• •Government healthcare reforms have expanded insurance reimbursement for diabetes medications and monitoring devices

The primary growth catalyst is the rising prevalence of diabetes in China, driven by aging demographics, urbanization, sedentary lifestyles, and dietary changes associated with economic development. Improved awareness and screening programs have increased diagnosis rates, bringing previously undetected cases into treatment pathways. Additionally, China's healthcare infrastructure expansion and growing insurance coverage have made diabetes therapies more accessible to broader population segments.

• •Aging population and rising obesity rates have increased diabetes incidence across urban and rural areas
• •Government initiatives under the Healthy China 2030 plan prioritize chronic disease management and screening
• •Expanding basic medical insurance coverage now includes more diabetes medications and devices

The market divides primarily into drug and device segments, with the drug category further broken into insulin, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, and other oral antidiabetics. The devices segment includes blood glucose monitoring systems, insulin pens and pumps, and emerging continuous glucose monitoring technologies. Geographically, demand concentrates in major urban centers and eastern coastal provinces with higher healthcare spending, though rural areas represent growing opportunities as medical infrastructure improves.

• •Insulin remains the dominant drug class, with rapid-acting and long-acting formulations driving significant revenue
• •Blood glucose monitoring devices represent the largest device category, while CGM adoption is accelerating
• •Eastern coastal regions account for the majority of market share, though central and western provinces show faster growth rates

What are the recent trends and outlook?

Emerging trends point toward increased adoption of digital health technologies, including continuous glucose monitoring systems and connected insulin delivery devices that integrate with mobile applications. GLP-1 receptor agonists and SGLT2 inhibitors are gaining market share as newer drug classes with additional cardiovascular and renal benefits. The market is expected to see continued consolidation of domestic manufacturing capabilities and potential price pressure as China promotes local production and competitive bidding for hospital procurement.

• •Continuous glucose monitoring adoption is accelerating as costs decline and insurance coverage expands
• •Domestic biosimilar development and local manufacturing are expected to reshape competitive dynamics through 2031
• •Digital therapeutics and telemedicine platforms are emerging as complementary components of diabetes care delivery